| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1013: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia |
|
Medicine details |
|
| Medicine name | quizartinib (VANFLYTA) |
| Formulation | 17.7 mg, 26.5 mg film-coated tablets |
| Reference number | 3686 |
| Indication | In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive |
| Company | Daiichi Sankyo |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/09/2024 |
| NICE guidance | |